Remove Clinical Trials Remove Hormones Remove Insulin
article thumbnail

There’s An Easier Way to Take Insulin, But It Hasn’t Been Tested on People Yet

AuroBlog - Aurous Healthcare Clinical Trials blog

The most effective way for people with diabetes to deliver insulin is also incredibly intrusive. Millions around the world must inject the crucial hormone underneath their skin several times a day to keep their glucose levels in balance.

Insulin 245
article thumbnail

(LAI-287 + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes.

Insulin 182
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sling Therapeutics’s Linsitinib Meets Primary Endpoint in Thyroid Eye Disease Trial, Eyes Competition with Amgen’s Tepezza

XTalks

Sling Therapeutics has positive topline results from its Phase IIb/III LIDS clinical trial evaluating its oral small-molecule therapy linsitinib for the treatment of thyroid eye disease (TED). It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone.

Trials 59
article thumbnail

Vykat XR Approved as First Treatment for Excessive Appetite in Prader-Willi Syndrome

XTalks

In the pancreas, potassium channels regulate insulin secretion. Since the FDA approved recombinant human growth hormone (rhGH) for PWS in 2000, multiple companies have tried and failed to develop a targeted treatment for hyperphagia. Based on the average weight of patients in its clinical trials, Vykat XR will cost $466,200 per year.

article thumbnail

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval

pharmaphorum

GLP-1 and GIP are hormones involved in blood sugar control and Mounjaro, a first-in-class medicine that activates both GLP-1 and GIP receptors, demonstrated improved blood sugar control. The findings were made via Lilly’s SURPASS phase 3 global clinical development programme, which comprised studies ranging from 40 to 52 weeks.

article thumbnail

NAFLD & NASH Clinical Trials: Viking Therapeutics Reports Positive Phase II Trial Data

XTalks

VK2809 is a novel, oral small molecule thyroid hormone receptor beta agonist that has selectivity for liver tissue. It is now seen as an epidemic within chronic liver disease, particularly as its prevalence has been increasing and paralleling that of obesity, making it a major health concern worldwide.

article thumbnail

Obesity Drug Petrelintide Advances into Phase IIb

XTalks

Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas. By mimicking this hormone, petrelintide may offer an alternative or complement to incretin-based therapies, known for their role in weight management.

Drugs 103